复方苦参注射液对放疗肺损伤的临床疗效及安全性观察

目的:探究复方苦参注射液对放疗性肺损伤防护作用及安全性。方法:选取我院胸外科收治的肺癌患者112例,随机分为两组,其中对照组57例,予常规单纯放疗治疗;实验组55例,在常规放疗治疗的同时加用复方苦参注射液5 m L,溶于0.9%氯化钠注射液250 m L,日一次静滴,至放疗结束。治疗结束后对比后两组患者放射性肺炎的比率、放射性肺纤维化比率及血浆TGF-β1和TNF-α值。结果:1放射治疗前两组血浆TGF-β1和TNF-α值无明显差异,无统计学意义(P0.05),放疗治疗后实验组血浆TGF-β1和TNF-α值较对照组明显下降,差异有统计学意义(P0.05),肺纤维化比率较对照组明显减低,差异有统计学意义(P0.05);2放疗治疗后实验组放射性肺炎的比率明显低于对照组,差异有统计学意义(P0.05);结论:复方苦参注射液够明显预防由于放射性治疗带来的肺损伤,对临床具有指导意义,值得临床推广。

Clinical Efficacy and Safety of Fufangkushen Injection on Radiation-induced Lung Injury

Objective:To explore the protective role of Fufangkushen injection on radiation -induced lung injury and its safety.Methods:112 lung cancer patients admitted to the Department of Thoracic Surgery in our hospital were selected and were randomly divided into two groups. 57 patients in control group received conventional radiotherapy and treatment; 55 cases in the experimental group were treated in the conventional radiotherapy combined with Compound Kushen injection 5 mL, dissolved in 0.9% Sodium Chloride Injection250 mL intravenous drip, once a day, to the end of radiotherapy. Ratios of radiation pneumonitis, radiation pulmonary fibrosis ratio and plasma TGF- beta 1 and TNF- alpha value were compared between the two groups after treatment.Results:TGF- beta 1 and alpha values had no significant differences between the two groups before treatment, with no statistical significance (P>0.05); after radiotherapy, TGF- beta 1 and TNF-alpha plasma TNF-decreased significantly in the experimental group, compared with that in the control group, and the difference was statistically significant (P < 0.05); what''s more, ratio of lung fibrosis, compared with that in the control group, decreased significantly, and there were statistically significant differences (P < 0.05); after radiotherapy, ratio of radioactive pneumoniawas in the experimental group was significantly lower than that in the control group, and the difference was statistically significant.Conclusion:Fufangkushen injection is effective in protecting the patients against radiation-induced lung damage, and it is worthy of clinical promotion.